Ark Bio Company

Ark is an end-to-end solution provider focused on cancer early detection. By harnessing advanced data science and proprietary miRNA detection technology, Ark develops non-invasive and cost-effective blood tests to detect early stage cancers before clinical symptoms appear. The company collaborates extensively with top medical research institutions globally and is spearheading Asia’s largest miRNA clinical studies targeting more than 50,000 participants. Ark is headquartered in Singapore, with R&D, manufacturing and clinical diagnostic operations in China and USA.
Technology: Other
Industry: Biotechnology, Medical
Headquarters: Singapore
Founded Date: 1-1
Employees Number: 11-50
Funding Status: Early Stage Venture
Last Funding Date: 43431
Last Funding Type: Series A

Visit Website
info@ark.bio
Register and Claim Ownership